Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | OGT | O15294 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 2/20 | 0.32 |
| ▸ | MMP2 | P08253 | 2/20 | 0.32 |
| ▸ | MMP9 | P14780 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13518063 | 0.88 | LMNA (0.36) | LMNAKDM4EOGTUSP2MAPT | |
| SCHEMBL11663614 | 0.86 | — | — | |
| SCHEMBL4379931 | 0.85 | LMNA (0.35) | LMNAKDM4EOGTUSP2MAPT | |
| SCHEMBL4386817 | 0.85 | LMNA (0.35) | LMNAKDM4EOGTUSP2MAPT | |
| SCHEMBL2640063 | 0.73 | PGR (0.34) | CRBN | |
| SCHEMBL13687818 | 0.70 | CRBN (0.34) | LMNACRBN | |
| SCHEMBL5988829 | 0.69 | CRBN (0.47) | CRBN | |
| SCHEMBL22018246 | 0.65 | LMNA (0.33) | LMNATP53 | |
| SCHEMBL22018250 | 0.65 | GRIN1 (0.34) | LMNAMMP13MMP2MMP9CRBN | |
| SCHEMBL10410273 | 0.65 | OTUD7B (0.36) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200147076-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2020-05-14 | — | — | US | claimed |
| US-20180296556-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2018-10-18 | — | — | US | claimed |
| US-20170172971-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2017-06-22 | — | — | US | claimed |
| EP-2701684-A1 | IMPROVED PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | Board Of Regents, The University Of Texas System (US) | 2014-03-05 | — | — | EP | claimed |
| WO-2012148799-A1 | IMPROVED PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-11-01 | — | — | WO | claimed |
| US-20120277249-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | GREENJAY THERAPEUTICS, INC. | 2012-11-01 | — | — | US | claimed |
| WO-2024151838-A1 | CO-CRYSTALS WITH THIN-FILM FREEZE-DRYING PROCESS TO ENHANCE DELIVERY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-18 | — | — | WO | disclosed |
| EP-4400491-A1 | NOVEL LIPIDS USED FOR NUCLEIC ACID DELIVERY AND LIPID NANOPARTICLE COMPOSITION | Themedium Therapeutics Co., Ltd (CN) | 2024-07-17 | — | — | EP | disclosed |
| US-20240216515-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-07-04 | — | — | US | disclosed |
| EP-4393484-A1 | COMPOSITION FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACID | Themedium Therapeutics Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| EP-4393511-A1 | LIPID COMPOUND AND USE THEREOF | Themedium Therapeutics Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| US-20240207178-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-06-27 | — | — | US | disclosed |
| US-20240197641-A1 | COMPOSITIONS AND METHODS FOR TARGETED SYSTEMIC DELIVERY TO CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-06-20 | — | — | US | disclosed |
| US-20170172971-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2017-06-22 | — | — | US | disclosed |
| EP-2701684-B1 | IMPROVED PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO LTD (US) | 2017-06-14 | — | — | EP | disclosed |
| US-20160346278-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | GREENJAY THERAPEUTICS, INC. | 2016-12-01 | — | — | US | disclosed |
| US-9364433-B2 | Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same | GREENJAY THERAPEUTICS, INC. | 2016-06-14 | — | — | US | disclosed |
| EP-2120871-B1 | LINKER-BASED LECITHIN MICROEMULSION DELIVERY VEHICLES | ACOSTA-ZARA EDGAR JOEL (CA) | 2014-11-26 | — | — | EP | disclosed |
| US-20120277249-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | GREENJAY THERAPEUTICS, INC. | 2012-11-01 | — | — | US | disclosed |
| US-20080139392-A1 | Linker-Based Lecithin Microemulsion Delivery Vehicles | ACOSTA-ZARA EDGAR JOEL | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207178-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | LMNA 350/4885KDM4E 4859/4885OGT 3716/4885 |
| US-20240216515-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | PNLIP, LIPA, PHOSPHO1 | LMNA 164/4885KDM4E 4050/4885OGT 4033/4885 |
| US-20240197641-A1 | COMPOSITIONS AND METHODS FOR TARGETED SYSTEMIC DELIVERY TO CELLS | SGMS2, SGMS1, LIPC | LMNA 519/4885KDM4E 4847/4885OGT 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.